CSF1R and acute myeloid leukemia: The efficacy of PLX3397, a FLT3 and CSF1R inhibitor, was demonstrated in relapsed/refractory FLT3-ITD-mutated AML with a safety profile similar to that of other FLT3 inhibitors [91].